

# Jose U Scher

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2908716/publications.pdf>

Version: 2024-02-01

94  
papers

8,820  
citations

66343

42  
h-index

54911

84  
g-index

102  
all docs

102  
docs citations

102  
times ranked

12710  
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to: "Microbiome in Sjögren's syndrome: here we are" by van der Meulen et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e115-e115.	0.9	0
2	Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS-CoV-2 Vaccination. <i>Arthritis and Rheumatology</i> , 2022, 74, 284-294.	5.6	103
3	Does biologic therapy impact the development of PsA among patients with psoriasis?. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 80-86.	0.9	29
4	Basic Science Session 2. Recent Advances in Our Understanding of Psoriatic Arthritis Pathogenesis. <i>Journal of Rheumatology</i> , 2022, , jrheum.211321.	2.0	1
5	GRAPPA 2020 Research Award Recipients. <i>Journal of Rheumatology</i> , 2022, , jrheum.211335.	2.0	0
6	COVID-19 outcomes in patients with psoriasis and psoriatic arthritis: A prospective cohort study. <i>JAAD International</i> , 2022, 8, 31-33.	2.2	2
7	Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease. <i>Lancet Rheumatology</i> , The, 2022, 4, e384-e387.	3.9	27
8	Psoriatic arthritis from a mechanistic perspective. <i>Nature Reviews Rheumatology</i> , 2022, 18, 311-325.	8.0	49
9	Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City. <i>Lancet Rheumatology</i> , The, 2022, 4, e582-e585.	3.9	9
10	Auto-deconvolution and molecular networking of gas chromatography-mass spectrometry data. <i>Nature Biotechnology</i> , 2021, 39, 169-173.	17.5	78
11	Prevalence, Predictors, and Disease Activity of Sacroiliitis Among Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 809-815.	1.9	5
12	CCL20 in psoriasis: A potential biomarker of disease severity, inflammation, and impaired vascular health. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 913-920.	1.2	26
13	Key opinion leaders "a critical perspective. <i>Nature Reviews Rheumatology</i> , 2021, 17, 119-124.	8.0	36
14	The Pretreatment Gut Microbiome Is Associated With Lack of Response to Methotrexate in New-Onset Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 931-942.	5.6	78
15	A comparison of physical function instruments in psoriatic arthritis: HAQ-DI vs MDHAQ vs PROMIS10 global physical health. <i>Rheumatology</i> , 2021, 60, 2307-2316.	1.9	9
16	Induction of remission in biologic-naive, severe psoriasis and PsA with dual anti-cytokine combination. <i>Rheumatology</i> , 2021, 60, e225-e226.	1.9	7
17	Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study. <i>Nature Reviews Rheumatology</i> , 2021, 17, 238-243.	8.0	23
18	Microbial-derived antigens and metabolites in spondyloarthritis. <i>Seminars in Immunopathology</i> , 2021, 43, 163-172.	6.1	10

#	ARTICLE	IF	CITATIONS
19	Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting. <i>Journal of Rheumatology</i> , 2021, , jrheum.201671.	2.0	6
20	Methotrexate impacts conserved pathways in diverse human gut bacteria leading to decreased host immune activation. <i>Cell Host and Microbe</i> , 2021, 29, 362-377.e11.	11.0	70
21	Another "BEE"? " Brain-Eye-Ear (BEE) Disease Secondary to HbSC Disease Masquerading as Multiple Sclerosis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 105618.	1.6	0
22	National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2"Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1254-1268.	1.2	88
23	Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1339-1344.	0.9	202
24	Editorial: Rheumatology at the center of coronavirus disease 2019: pathogenesis, treatment, and clinical care. <i>Current Opinion in Rheumatology</i> , 2021, 33, 409-411.	4.3	0
25	Multimodal single-cell analysis of cutaneous T-cell lymphoma reveals distinct subclonal tissue-dependent signatures. <i>Blood</i> , 2021, 138, 1456-1464.	1.4	39
26	Moving the Goalpost Toward Remission: The Case for Combination Immunomodulatory Therapies in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1574-1578.	5.6	6
27	Psoriatic arthritis. <i>Nature Reviews Disease Primers</i> , 2021, 7, 59.	30.5	113
28	Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort. <i>Lancet Rheumatology</i> , The, 2021, 3, e585-e594.	3.9	18
29	New Frontiers in Psoriatic Disease Research, Part I: Genetics, Environmental Triggers, Immunology, Pathophysiology, and Precision Medicine. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2112-2122.e3.	0.7	19
30	1206"..."Evaluation of SARS-CoV-2 IgG antibody reactivity in a multi-racial/ethnic cohort of patients with systemic lupus erythematosus. , 2021, , .		2
31	A Randomized Open Label Clinical Trial of Lipid-Lowering Therapy in Psoriasis to Reduce Vascular Endothelial Inflammation.. <i>Journal of Investigative Dermatology</i> , 2021, , .	0.7	13
32	Measuring Outcomes in Psoriatic Arthritis: Comparing Routine Assessment of Patient Index Data and Psoriatic Arthritis Impact of Disease. <i>Journal of Rheumatology</i> , 2020, 47, 1496-1505.	2.0	14
33	Interleukin"17 Inhibition in Spondyloarthritis Is Associated With Subclinical Gut Microbiome Perturbations and a Distinctive Interleukin"25"Driven Intestinal Inflammation. <i>Arthritis and Rheumatology</i> , 2020, 72, 645-657.	5.6	51
34	Leveraging the United States Epicenter to Provide Insights on COVID"19 in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2020, 72, 1971-1980.	5.6	51
35	COVID"19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease"Modifying Antirheumatic Drugs on Clinical Outcomes. <i>Arthritis and Rheumatology</i> , 2020, 72, 1981-1989.	5.6	92
36	Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMAN. <i>Current Rheumatology Reports</i> , 2020, 22, 78.	4.7	10

#	ARTICLE	IF	CITATIONS
37	National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1704-1716.	1.2	43
38	Not your average joint: Towards precision medicine in psoriatic arthritis. <i>Clinical Immunology</i> , 2020, 217, 108470.	3.2	9
39	Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response. <i>Nature Reviews Rheumatology</i> , 2020, 16, 282-292.	8.0	76
40	Activated Platelets Induce Endothelial Cell Inflammatory Response in Psoriasis via COX-1. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 1340-1351.	2.4	56
41	Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. <i>Lancet, The</i> , 2020, 395, 427-440.	13.7	122
42	Covid-19 in Immune-Mediated Inflammatory Diseases – Case Series from New York. <i>New England Journal of Medicine</i> , 2020, 383, 85-88.	27.0	377
43	The microbiome in rheumatology: Where are we and where should we go?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 727-733.	0.9	55
44	Interleukin 1 receptor antagonist ( <i>IL1RN</i> ) gene variants predict radiographic severity of knee osteoarthritis and risk of incident disease. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 400-407.	0.9	35
45	KLK6 expression in skin induces PAR1-mediated psoriasiform dermatitis and inflammatory joint disease. <i>Journal of Clinical Investigation</i> , 2020, 130, 3151-3157.	8.2	34
46	Distinct Polysaccharide Utilization Profiles of Human Intestinal <i>Prevotella copri</i> Isolates. <i>Cell Host and Microbe</i> , 2019, 26, 680-690.e5.	11.0	115
47	Inflammasome Signaling and Impaired Vascular Health in Psoriasis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 787-798.	2.4	66
48	Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. <i>Nature Reviews Rheumatology</i> , 2019, 15, 153-166.	8.0	208
49	OP0108 – DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSA: OVERALL AND TNF-INHIBITOR-NAÏVE POPULATION RESULTS FROM A 48-WEEK PHASE 2B RANDOMISED STUDY. , 2019, , .		6
50	Strategies to Improve Outcomes in Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2019, 21, 72.	4.7	19
51	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019, 4, 31-58.	0.7	12
52	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 5-32.	5.6	312
53	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2019, 71, 2-29.	3.4	264
54	Microbiome and Microbiota in Rheumatic Disease. , 2019, , 11-19.		0

#	ARTICLE	IF	CITATIONS
55	Augmented Th17 Differentiation Leads to Cutaneous and Synovial Enteseal Inflammation in a Novel Model of Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 855-867.	5.6	29
56	The role of the gut microbiome in systemic inflammatory disease. <i>BMJ: British Medical Journal</i> , 2018, 360, j5145.	2.3	367
57	Gut Microbiota Perturbations in Reactive Arthritis and Postinfectious Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 242-254.	5.6	88
58	The 2018 landscape of RA, PsA, and SpA pathogenesis. <i>Current Opinion in Rheumatology</i> , 2018, 30, 57-58.	4.3	3
59	Potential risk factors for reactive arthritis and persistence of symptoms at 2 years: a case-control study with longitudinal follow-up. <i>Clinical Rheumatology</i> , 2018, 37, 415-422.	2.2	7
60	Microbiota-Dependent Involvement of Th17 Cells in Murine Models of Inflammatory Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1971-1983.	5.6	37
61	The Microbiome in Psoriasis and Psoriatic Arthritis: Joints. <i>Journal of Rheumatology</i> , 2018, 94, 32-35.	2.0	18
62	Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) Survey: Benefits and Challenges of Combined Rheumatology-dermatology Clinics. <i>Journal of Rheumatology</i> , 2017, 44, 693-694.	2.0	33
63	Partial elimination of intestinal microbiota dampens t helper 17 cell differentiation and established collagen-induced arthritis in mice. , 2017, , .		0
64	Human microbiome, infections, and rheumatic disease. <i>Clinical Rheumatology</i> , 2017, 36, 2645-2653.	2.2	26
65	Alteration of the intestinal microbiome characterizes preclinical inflammatory arthritis in mice and its modulation attenuates established arthritis. <i>Scientific Reports</i> , 2017, 7, 15613.	3.3	100
66	Aberrant intestinal microbiota due to IL-1 receptor antagonist deficiency promotes IL-17- and TLR4-dependent arthritis. <i>Microbiome</i> , 2017, 5, 63.	11.1	73
67	Short- and long-term effects of oral vancomycin on the human intestinal microbiota. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 128-136.	3.0	233
68	Gene, environment, microbiome and mucosal immune tolerance in rheumatoid arthritis. <i>Rheumatology</i> , 2016, 55, keu469.	1.9	62
69	Review: Microbiome in Inflammatory Arthritis and Human Rheumatic Diseases. <i>Arthritis and Rheumatology</i> , 2016, 68, 35-45.	5.6	187
70	The lung microbiota in early rheumatoid arthritis and autoimmunity. <i>Microbiome</i> , 2016, 4, 60.	11.1	158
71	Periodontal Infections and Rheumatoid Arthritis. , 2016, , 107-115.		0
72	The metabolic role of the gut microbiota in health and rheumatic disease: mechanisms and interventions. <i>Nature Reviews Rheumatology</i> , 2016, 12, 446-455.	8.0	112

#	ARTICLE	IF	CITATIONS
73	The microbiome in celiac disease: Beyond diet-genetic interactions. <i>Cleveland Clinic Journal of Medicine</i> , 2016, 83, 228-230.	1.3	5
74	Reply. <i>Arthritis and Rheumatology</i> , 2015, 67, 2280-2282.	5.6	0
75	Decreased Bacterial Diversity Characterizes the Altered Gut Microbiota in Patients With Psoriatic Arthritis, Resembling Dysbiosis in Inflammatory Bowel Disease. <i>Arthritis and Rheumatology</i> , 2015, 67, 128-139.	5.6	602
76	Spondyloarthritis and the Microbiome: New Insights From an Ancient Hypothesis. <i>Current Rheumatology Reports</i> , 2015, 17, 10.	4.7	16
77	Intestinal Dysbiosis and Potential Consequences of Microbiome-altering Antibiotic Use in the Pathogenesis of Human Rheumatic Disease. <i>Journal of Rheumatology</i> , 2015, 42, 355-357.	2.0	7
78	The microbiome in rheumatic diseases. , 2015, , 145-151.		0
79	Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 16814-16819.	7.1	185
80	Microbiome and mucosal inflammation as extra-articular triggers for rheumatoid arthritis and autoimmunity. <i>Current Opinion in Rheumatology</i> , 2014, 26, 101-107.	4.3	187
81	Periodontal disease and subgingival microbiota as contributors for rheumatoid arthritis pathogenesis. <i>Current Opinion in Rheumatology</i> , 2014, 26, 424-429.	4.3	81
82	Biomarkers in Psoriatic Arthritis: Recent Progress. <i>Current Rheumatology Reports</i> , 2014, 16, 453.	4.7	21
83	Association of medication beliefs and self-efficacy with adherence in urban Hispanic and African-American rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 317-318.	0.9	22
84	Periodontal disease, <i>Porphyromonas gingivalis</i> , and rheumatoid arthritis: what triggers autoimmunity and clinical disease?. <i>Arthritis Research and Therapy</i> , 2013, 15, 122.	3.5	45
85	Expansion of intestinal <i>Prevotella copri</i> correlates with enhanced susceptibility to arthritis. <i>ELife</i> , 2013, 2, e01202.	6.0	1,507
86	Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 3083-3094.	6.7	399
87	B-cell therapies for rheumatoid arthritis. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2012, 70, 200-3.	0.7	16
88	The microbiome and rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2011, 7, 569-578.	8.0	381
89	The Anti-Inflammatory Effects of Prostaglandins. <i>Journal of Investigative Medicine</i> , 2009, 57, 703-708.	1.6	206
90	<i>Helicobacter pylori</i> Stimulates Gastric Epithelial Cell MMP-1 Secretion via CagA-dependent and -independent ERK Activation. <i>Journal of Biological Chemistry</i> , 2007, 282, 18722-18731.	3.4	57

#	ARTICLE	IF	CITATIONS
91	Nitric oxide synthases and osteoarthritis. <i>Current Rheumatology Reports</i> , 2007, 9, 9-15.	4.7	71
92	Matrix Metalloproteinase Secretion by Gastric Epithelial Cells Is Regulated by E Prostaglandins and MAPKs. <i>Journal of Biological Chemistry</i> , 2005, 280, 9973-9979.	3.4	48
93	15d-PGJ2: The anti-inflammatory prostaglandin?. <i>Clinical Immunology</i> , 2005, 114, 100-109.	3.2	298
94	Neutrophils I. , 0, , 39-48.		0